JAMA clinical practice review on peripheral artery disease (PAD) covering diagnosis with ankle-brachial index, functional impact, and evidence-based pharmacological management including explicit mention of semaglutide among recommended therapies for cardiovascular event prevention in PAD patients. Documents semaglutide's incorporation into PAD clinical practice guidelines alongside statins, antiplatelet agents, and blood pressure control. Establishes semaglutide as a guideline-endorsed cardiovascular risk reduction therapy specifically in PAD—an underrecognized population with very high MACE risk where GLP-1 RA benefit is now guideline-supported.
McDermott, Mary M